Form D · Pharmaceuticals
Aprecia Pharmaceuticals Co
Langhorne, PA · CIK 0001299458
Offering snapshot reported Jan 28, 2016 · SEC filing
- Reported sold
- $79M Offering amount: $84M
- Investors reported
- 20 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 13, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 28, 2016 | Initial | $78,996,852 | No comparison | 20 | SEC filing |
| Aug 31, 2015 | Initial | $38,750,000 | No comparison | 8 | SEC filing |
| Dec 10, 2013 | Amendment | $14,893,829 | $0vs Dec 9, 2013 | 1 | SEC filing |
| Dec 9, 2013 | Initial | $14,893,829 | No comparison | 1 | SEC filing |
| Nov 19, 2012 | Initial | $4,000,000 | No comparison | 1 | SEC filing |
| Nov 4, 2011 | Initial | $25,725,261 | No comparison | 1 | SEC filing |
| Dec 20, 2010 | Amendment | $3,940,402 | $3,835,402vs Oct 18, 2010 | 1 | SEC filing |
| Nov 8, 2010 | Amendment | $455,000 | $350,000vs Oct 18, 2010 | 1 | SEC filing |
| Oct 18, 2010 | Initial | $105,000 | No comparison | 1 | SEC filing |
| Jan 25, 2010 | Amendment | $5,500,000 | $3,000,000vs Dec 24, 2009 | 1 | SEC filing |
| Dec 24, 2009 | Initial | $2,500,000 | No comparison | 1 | SEC filing |
| May 29, 2009 | Initial | $500,000 | No comparison | Not reported | SEC filing |
| Jan 15, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $3.17M
- Finders' fees
- $0
- Form D file number
- 021-256143
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| MTS Securities, LLC | 104059 |
Source: Form D, filed Jan 28, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| E Thomas Arington | Director |
| James Evans | Director |
| David Furniss | Executive |
| Lawrence Glassmann | Director |
| Joseph Highland | Director |
| Michael King | Executive |
| Jonathan Leff | Director |
| Donald C. Monkhouse | Executive |
| Etienne Perold | Director |
| Michael Rohlfs | Executive |
| Michael Rolhfs | Executive |
| Henry Surprenant | Executive |
| Glenn S. Vraniak | Executive |
| Don Wetherhold | Executive |
| Donald Wetherhold | Executive |
| Robert Williford | Executive |
| Jaedeok Yoo | Executive |
| Jaedok Yoo | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
2010 Cabot Boulevard West Suite F
Langhorne, PA, 19047
Langhorne, PA, 19047